- Home
- CRDF vs SRV Comparison
CRDF vs SRV Comparison
Compare CRDF & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- SRV
- Stock Information
- Founded
- CRDF 1999
- SRV 2007
- Country
- CRDF United States
- SRV United States
- Employees
- CRDF N/A
- SRV N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- SRV Finance Companies
- Sector
- CRDF Health Care
- SRV Finance
- Exchange
- CRDF Nasdaq
- SRV Nasdaq
- Market Cap
- CRDF 143.4M
- SRV 121.8M
- IPO Year
- CRDF N/A
- SRV N/A
- Fundamental
- Price
- CRDF $2.58
- SRV $43.46
- Analyst Decision
- CRDF Strong Buy
- SRV
- Analyst Count
- CRDF 3
- SRV 0
- Target Price
- CRDF $9.33
- SRV N/A
- AVG Volume (30 Days)
- CRDF 1.1M
- SRV 33.9K
- Earning Date
- CRDF 11-07-2024
- SRV 01-01-0001
- Dividend Yield
- CRDF N/A
- SRV 13.38%
- EPS Growth
- CRDF N/A
- SRV N/A
- EPS
- CRDF N/A
- SRV N/A
- Revenue
- CRDF $688,000.00
- SRV N/A
- Revenue This Year
- CRDF $15.00
- SRV N/A
- Revenue Next Year
- CRDF N/A
- SRV N/A
- P/E Ratio
- CRDF N/A
- SRV N/A
- Revenue Growth
- CRDF 49.57
- SRV N/A
- 52 Week Low
- CRDF $1.07
- SRV $30.73
- 52 Week High
- CRDF $6.42
- SRV $44.30
- Technical
- Relative Strength Index (RSI)
- CRDF 41.24
- SRV 50.00
- Support Level
- CRDF $2.85
- SRV $42.70
- Resistance Level
- CRDF $4.38
- SRV $45.91
- Average True Range (ATR)
- CRDF 0.45
- SRV 1.10
- MACD
- CRDF -0.10
- SRV 0.19
- Stochastic Oscillator
- CRDF 2.70
- SRV 59.57
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.